Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10238	Companies
211363	Keywords
141296	Articles
111973	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 06/06/2024 at 13:00, 1 year 10 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Moderna's mRNA-3705 selected for FDA's START pilot program to address rare diseases. The investigational mRNA therapeutic aims to treat methylmalonic acidemia due to MUT deficiency with innovative mRNA platform

Moderna Rare Diseases MMA MRNA-3705 START Pilot Program
PRESS RELEASE

published on 06/03/2024 at 14:00, 1 year 10 months ago

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage II
BRIEF

published on 05/31/2024 at 17:03, 1 year 10 months ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA

FDA Approval Moderna Vaccine RSV MRESVIA
PRESS RELEASE

published on 05/31/2024 at 16:58, 1 year 10 months ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
Moderna gains FDA approval for mRESVIA, a single-dose pre-filled syringe RSV vaccine for adults 60+ to prevent lower respiratory tract disease. Second mRNA product and breakthrough therapy designation

FDA Approval Moderna RSV Vaccine MRNA MRESVIA
BRIEF

published on 05/22/2024 at 13:05, 1 year 10 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Clinical Trials Immunotherapy Moderna ASCO 2024 MRNA-4157
PRESS RELEASE

published on 05/22/2024 at 13:00, 1 year 10 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna to host an investor event via webcast on June 3 at 6:15 PM CDT. Abstracts on mRNA-4157 for ASCO Annual Meeting. Details on mRNA-4157 (V940) therapy development

Webcast Moderna Investor Event MRNA-4157 Neoantigen Therapy
BRIEF

published on 05/13/2024 at 13:05, 1 year 11 months ago

Moderna Announces Participation in Key Investor Conferences

Investor Conferences Healthcare Financial Markets Moderna Webcasts
PRESS RELEASE

published on 05/13/2024 at 13:00, 1 year 11 months ago

Moderna to Present at Upcoming Conferences in May/June 2024
Moderna, Inc. to participate in upcoming investor conferences, showcasing its leadership in mRNA medicine and innovative approach to disease treatment. Live webcasts available

Investor Conferences Moderna Inc. MRNA Medicine Webcasts Disease Treatment
BRIEF

published on 05/02/2024 at 12:35, 1 year 11 months ago

Moderna Reports Q1 2024 Financial Performance and Strategic Progress

Financial Results MRNA Technology Moderna RSV Vaccine Vaccine Development
PRESS RELEASE

published on 05/02/2024 at 12:30, 1 year 11 months ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024

Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula

Accesswire

Published on 04/18/2026 at 04:00, 14 hours 27 minutes ago

Formation Metals Responds to OTC Markets Request on Recent Promotional Activity
Published on 04/18/2026 at 02:00, 16 hours 27 minutes ago

AI/ML Innovations Announces Completion of Share Issuance
Published on 04/18/2026 at 01:35, 16 hours 52 minutes ago

Medicure Announces Resignation of President and Chief Operating Officer
Published on 04/18/2026 at 01:00, 17 hours 27 minutes ago

Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Published on 04/18/2026 at 00:00, 18 hours 27 minutes ago

Redwood AI Announces Collaboration with Aidos Innovations, Aimed at Enhancing Public Safety Collaboration with B.C. Government, Canadian Federal and Local Law Enforcement Agencies to Tackle the Fentanyl Crisis in British Columbia

View all ACCESSWIRE

EQS Group

Published on 04/18/2026 at 00:05, 18 hours 22 minutes ago

ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
Published on 04/17/2026 at 20:33, 21 hours 53 minutes ago

LLB General Meeting 2026 – Shareholders approve all proposals of the Board of Directors
Published on 04/17/2026 at 19:35, 22 hours 52 minutes ago

Stabilisation Notice
Published on 04/17/2026 at 19:30, 22 hours 56 minutes ago

KAP AG: REFINANCING CONCEPT AGREED; NEW SYNDICATED LOAN SECURES FLEXIBILITY FOR THE ONGOING TRANSFORMATION PROCESS
Published on 04/17/2026 at 19:29, 22 hours 57 minutes ago

EQS-Adhoc: KAP AG: KAP AG: REFINANCING CONCEPT AGREED; TERM OF EXISTING SYNDICATED LOAN EXTENDED BY THREE YEARS

Les Echos

Published on 04/17/2026 at 19:00, 23 hours 27 minutes ago

Cegedim: Release of its 2025 Universal Registration Document
Published on 04/17/2026 at 17:45, 1 day ago

Carrefour announces the sale of its minority stake in CarrefourSA in Turkey to Aydın
Published on 04/17/2026 at 15:26, 1 day 3 hours ago

Statement about the number of shares composing the share capital and the number of voting rights as of March 31, 2026
Published on 04/17/2026 at 09:10, 1 day 9 hours ago

Number of shares and voting rights - March 2026 (In French only)
Published on 04/16/2026 at 18:02, 2 days ago

Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026

View all LES ECHOS COMFI WIRE